Robert J. Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Biocatalysis and Metabolic Engineering at Rensselaer, is part of an international team that recently announced it had uncovered the source of the deadly contamination. On April 23, the team led by researchers at the Massachusetts Institute of Technology (MIT), described the source in the journal Nature Biotechnology -- a complex carbohydrate named oversulfated chondroitin sulfate, which has a structure so similar to heparin it was nearly undetectable to less advanced technology.
"Days after the deaths were first linked to heparin, we had the drugs in our hands from the FDA and our nuclear magnetic resonator (NMR) was set into motion to break down the structure of the drug and determine what could possibly be the source of the contamination," Linhardt said. "Now that we know the most likely source of the contamination, we are developing much stronger monitoring systems to ensure that this type of contamination is detected before it reaches patients."
Although extremely close in chemical structure to heparin, the contaminant caused severe allergic reaction in many patients who were receiving routine treatment for kidney dialysis, heart surgery, and other common medical issues. The researchers' extremely detailed structural analysis of the drug, using technology such as the NMR, was able to detect the minute differences between the contaminated drug and a normal dosage of heparin. And while Linhardt and others are developing more sophisticated detection systems, Linhardt also is helping lead the race for a safer, man-made alternative to the traditional biologic heparin. Biological heparin is currently developed by purifying the scrapings of pig and cow intestines.
"This contamination is unfortunately a sign that the way we currently manufacture heparin is simply unsafe," he said. "Because we rely on animals, we open ourselves up for spreading prions and diseases like mad cow disease through these animals. And because most of the raw material is imported, we often can't be sure of exactly what we are getting."
Linhardt is helping lead the global race to develop a synthetic alternative to heparin that could help eliminate the potential for contamination and adverse affects of biologic heparin. His lab developed the first fully synthetic heparin in amounts large enough for human dosage in 2005, and he continues to work to get the product further tested and commercialized.
"A synthetic heparin is built using sugars and enzymes found in the human body," Linhardt said of his recipe for synthetic heparin. "So instead of taking pig intestines and trying to purify it over and over again to reduce it down to just heparin, we are building heparin from scratch with no foreign material present. This method ensures that we know exactly what is in the drug and have complete control over its ingredients."
The research published in Nature Biotechnology was led by Ram Sasisekharan at MIT and involved a multidisciplinary and global team of researchers, including scientists and engineers from the FDA, Momenta Pharmaceuticals of Cambridge, Mass., and the Istituto di Ricerche Chimiche e Biochimiche of Milan, Italy.
Linhardt and his team of researchers at Rensselaer, which includes postdoctoral, graduate, and undergraduate students, used the sophisticated NMR and other technologies in the Rensselaer Center for Biotechnology and Interdisciplinary Studies (CBIS) to help uncover the source of the contamination.
Rensselaer Polytechnic Institute, founded in 1824, is the nation's oldest technological university. The university offers bachelor's, master's, and doctoral degrees in engineering, the sciences, information technology, architecture, management, and the humanities and social sciences. Institute programs serve undergraduates, graduate students, and working professionals around the world. Rensselaer faculty are known for pre-eminence in research conducted in a wide range of fields, with particular emphasis in biotechnology, nanotechnology, information technology, and the media arts and technology. The Institute is well known for its success in the transfer of technology from the laboratory to the marketplace so that new discoveries and inventions benefit human life, protect the environment, and strengthen economic development.
About the Rensselaer Center for Biotechnology and Interdisciplinary Studies
Ranked among the world's most advanced research facilities, the Rensselaer Center for Biotechnology and Interdisciplinary Studies provides a state-of-the-art platform for collaborative research. At the Center, faculty and students in diverse academic and research disciplines are crossing the divide between the life sciences and engineering to encourage discovery and innovation. Four biotechnology research constellations - biocatalysis and metabolic engineering, functional tissue engineering and regenerative medicine, biocomputation and bioinformatics, and integrative systems biology - engage a multidisciplinary mix of faculty and students to help create new technologies that will save and improve the lives of people around the world.
Gabrielle DeMarco | EurekAlert!
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences